JP2009525324A5 - - Google Patents

Download PDF

Info

Publication number
JP2009525324A5
JP2009525324A5 JP2008553201A JP2008553201A JP2009525324A5 JP 2009525324 A5 JP2009525324 A5 JP 2009525324A5 JP 2008553201 A JP2008553201 A JP 2008553201A JP 2008553201 A JP2008553201 A JP 2008553201A JP 2009525324 A5 JP2009525324 A5 JP 2009525324A5
Authority
JP
Japan
Prior art keywords
disease
dementia
salt
disorder
cognitive impairment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2008553201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525324A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2007/000086 external-priority patent/WO2007089191A1/en
Publication of JP2009525324A publication Critical patent/JP2009525324A/ja
Publication of JP2009525324A5 publication Critical patent/JP2009525324A5/ja
Ceased legal-status Critical Current

Links

JP2008553201A 2006-02-02 2007-01-31 インドール誘導体の新規なクエン酸塩およびその医薬用途 Ceased JP2009525324A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76455106P 2006-02-02 2006-02-02
PCT/SE2007/000086 WO2007089191A1 (en) 2006-02-02 2007-01-31 New citrate salt of an indole derivative and its pharmaceutical use

Publications (2)

Publication Number Publication Date
JP2009525324A JP2009525324A (ja) 2009-07-09
JP2009525324A5 true JP2009525324A5 (enExample) 2010-03-04

Family

ID=38327680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008553201A Ceased JP2009525324A (ja) 2006-02-02 2007-01-31 インドール誘導体の新規なクエン酸塩およびその医薬用途

Country Status (24)

Country Link
US (2) US8008294B2 (enExample)
EP (1) EP1981869A4 (enExample)
JP (1) JP2009525324A (enExample)
KR (1) KR20080098022A (enExample)
CN (2) CN101378754A (enExample)
AR (1) AR059225A1 (enExample)
AU (1) AU2007210336B2 (enExample)
BR (1) BRPI0706745A2 (enExample)
CA (1) CA2641900A1 (enExample)
EC (1) ECSP088647A (enExample)
IL (1) IL192888A0 (enExample)
MX (1) MX2008009719A (enExample)
MY (1) MY146102A (enExample)
NO (1) NO20083784L (enExample)
NZ (1) NZ570849A (enExample)
PE (1) PE20090192A1 (enExample)
RU (1) RU2415137C2 (enExample)
SA (1) SA07280004B1 (enExample)
SG (1) SG169381A1 (enExample)
TW (1) TW200800977A (enExample)
UA (1) UA94251C2 (enExample)
UY (1) UY30126A1 (enExample)
WO (1) WO2007089191A1 (enExample)
ZA (1) ZA200806725B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
CN101679353A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 制备化合物2-羟基-3-[5-(吗啉-4-基甲基)吡啶-2-基]1h-吲哚-5-腈701的新方法
US20100267720A1 (en) * 2007-07-30 2010-10-21 Astrazeneca Ab Crystalline Forms of 2-Hydroxy-3- [5- (Morpholin- 4- Ylmethyl) Pyridin-2-YL] IH- Indole- 5 -Carbonitrile Citrate
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN120441567A (zh) * 2020-04-07 2025-08-08 Crt先锋基金有限公司 Chk1抑制剂的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1373263T1 (en) 2001-04-05 2005-04-30 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetic vascular complications
JP2003009588A (ja) 2001-06-20 2003-01-10 Toshiba Corp 車両連続運転装置用インバータ装置
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
JP2007502300A (ja) * 2003-08-13 2007-02-08 カイロン コーポレイション Gsk−3インヒビターおよびその使用
MX2007008008A (es) 2004-12-30 2007-11-12 Astex Therapeutics Ltd Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات

Similar Documents

Publication Publication Date Title
JP2010535200A5 (enExample)
ME03809B (me) KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
JP2017531020A5 (enExample)
FI3792254T3 (fi) Kiteisiä metyylitioniniumkloridihydraatteja
JP2017524733A5 (enExample)
RU2015143466A (ru) Нейроактивные стероиды и способы их применения
JP2022502500A5 (enExample)
JP2021527031A5 (enExample)
JP2013536833A5 (enExample)
RU2008148325A (ru) Полиморфные формы(2s)-(4е)-n-метил-5-(3-изопропоксипиридин)ил) 4-пентен-2амина для лечения расстройств центральной нервной системы
JP2010514725A5 (enExample)
JP2009534373A5 (enExample)
JP2017538753A5 (enExample)
JP2021534227A5 (enExample)
RU2008131906A (ru) Новая цитратная соль производного индола и ее фармацевтическое применение
JP2007519697A5 (enExample)
JP2018514507A5 (enExample)
HRP20140326T1 (hr) Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat
JP2020507567A5 (enExample)
RU2019128576A (ru) Сокристаллы замещенных глициновых соединений и их применение
JP2019518756A5 (enExample)
JP2009528344A5 (enExample)
JP2011500819A5 (enExample)
JP2009536665A5 (enExample)
JP2009510162A5 (enExample)